Boston Scientific looks to lead the drug-eluting PAD market

Angioplasty is not a new procedure – doctors have been widening obstructed arteries with balloons since the 1960s. But for years the medtech industry has been plagued with what Jeff Mirviss, president of Boston Scientific’s interventional peripheral biz, calls the procedure’s Achilles heel: Restenosis.

For patients treated with bare balloons, half must have the procedure done again because their arteries have re-clogged. Stents improved that rate to 1 of every 3 or 4 patients, Mirviss told Drug Delivery Business News. But drug-coated balloons designed to control scar tissue formation can bring the rate down to 1 in 20 patients.

Boston Scientific (NYSE:BSX) has a prolific portfolio of peripheral intervention devices, including their Ranger paclitaxel-coated PTA balloon catheter. In a study of 105 patients with femoropoliteal lesions, the balloon yielded 86% primary patency and 91% freedom from total lesion revascularization at 12 months, lessening the need for re-interventions. Both findings were statistically significantly higher than the control arm of patients, who were treated with a bare balloon.

Get the full story at our sister site, Drug Delivery Business News.

The post Boston Scientific looks to lead the drug-eluting PAD market appeared first on MassDevice.

from MassDevice http://ift.tt/2qeTqbo